IRB #

STUDY00018380

Title

An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Principal Investigator

Rachel Cook

Study Purpose

This is an expanded access, open-label, multicenter program of ruxolitinib for treatment of chronic GVHD, for patients who have received a bone marrow transplant (allogeneic hematopoietic stem cell transplant, or allo-HSCT) and developed GVHD not responsive to steroid treatment and who are not eligible to participate in an actively-enrolling study for treatment of GVHD sponsored by the pharmaceutical company Incyte Corporation within the US.

Medical Condition(s)

Chronic Graft-versus-Host disease
Chronic GVHD
Steroid refractory or intolerant cGVHD

Eligibility Criteria

Patients who have steroid refractory or intolerant chronic graft-versus-host disease (cGVHD).

Age Range

12 - 100

Healthy Volunteers Needed

No

Duration of Participation

Eligible patients may receive ruxolitinib treatment for as long as clinical benefit is observed and/or treatment withdrawal criteria are not met as per discretion of treating physician.

Minors Included

Yes

Contact

Knight Cancer Intake Center: (503)494-7999
Clinical Trials Information Line: (503)­494-­1080 or trials@ohsu.edu

Sponsor

Incyte Corporation

Recruitment End

03/31/2027

Compensation Provided

No


Go Back